Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia
-
Shang-Jyh Kao
und
Ming-Hsien Chien
Abstract
Background: Endothelial cell-specific molecule (ESM)-1 is a soluble proteoglycan expressed by the vascular endothelium and which also circulates in the bloodstream. Inflammatory cytokines and proangiogenic growth factors increase its expression, and increased serum levels are found in immunocompetent patients with sepsis. The aim of this study was to investigate differential changes in plasma levels of ESM-1 before and after antibiotic treatment in hospitalized adult patients with community-acquired pneumonia (CAP).
Methods: Plasma ESM-1 levels were measured in 82 adult patients with CAP and 82 healthy controls using a commercial enzyme-linked immunosorbent assay (ELISA). Upon initial hospitalization, Acute Physiology and Chronic Health Evaluation II (APACHE II), CURB-65, and Pneumonia Severity Index (PSI) scores were determined to assess CAP severity in these patients.
Results: Results showed a decline in the number of white blood cells (WBCs) and neutrophils, and decreases in the concentrations of C-reactive protein (CRP) and ESM-1 after antibiotic treatment. The plasma concentration of ESM-1, but not CRP or the WBC count, was correlated with the severity of CAP based on the PSI (r=0.554, p<0.001), CURB-65 (r=0.510, p<0.001), and APACHE II scores (r=0.447, p<0.001).
Conclusions: Plasma levels of ESM-1 may be able to play a role in the diagnosis and clinical assessment of the severity of CAP, which could potentially guide the development of treatment strategies.
This study was supported by a grant (SKH-TMU-102-04) from Shin Kong Wu Ho-Su Memorial Hospital.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research funding played no role in thestudy design; in the collection, analysis, and interpretationof data; in the writing of the report; or in the decision tosubmit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection 2004;32:234–8.10.1007/s15010-004-3107-zSuche in Google Scholar PubMed
2. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl 3):iii3–9.10.1093/jac/dkr094Suche in Google Scholar PubMed PubMed Central
3. Lee YT, Chen SC, Shyu LY, Lee MC, Wu TC, Tsao SM, et al. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia. Clin Chim Acta 2012;413:630–5.10.1016/j.cca.2011.12.010Suche in Google Scholar PubMed
4. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637–44.10.1001/archinte.164.6.637Suche in Google Scholar PubMed
5. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865–9.10.1378/chest.07-0164Suche in Google Scholar PubMed
6. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect 2011;17(Suppl 6): E1–59.10.1111/j.1469-0691.2011.03672.xSuche in Google Scholar PubMed PubMed Central
7. Almirall J, Bolibar I, Toran P, Pera G, Boquet X, Balanzo X, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004;125:1335–42.10.1378/chest.125.4.1335Suche in Google Scholar PubMed
8. Holm A, Nexoe J, Bistrup LA, Pedersen SS, Obel N, Nielsen LP, et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007;57:547–54.Suche in Google Scholar
9. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458–64.10.1074/jbc.271.34.20458Suche in Google Scholar PubMed
10. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37:417–25.10.1159/000025758Suche in Google Scholar PubMed
11. Wellner M, Herse F, Janke J, Gorzelniak K, Engeli S, Bechart D, et al. Endothelial cell specific molecule-1 – a newly identified protein in adipocytes. Horm Metab Res 2003;35:217–21.10.1055/s-2003-39477Suche in Google Scholar PubMed
12. Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167:3099–106.10.4049/jimmunol.167.6.3099Suche in Google Scholar PubMed
13. Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, et al. Overexpression of endocan induces tumor formation. Cancer Res 2003;63:6084–9.Suche in Google Scholar
14. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006;34:532–7.10.1097/01.CCM.0000198525.82124.74Suche in Google Scholar PubMed
15. Mikkelsen ME, Shah CV, Scherpereel A, Lanken PN, Lassalle P, Bellamy SL, et al. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2012;27:522 e511–27.10.1016/j.jcrc.2011.07.077Suche in Google Scholar PubMed PubMed Central
16. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27–72.10.1086/511159Suche in Google Scholar PubMed PubMed Central
17. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336: 243–50.10.1056/NEJM199701233360402Suche in Google Scholar PubMed
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–29.10.1097/00003246-198510000-00009Suche in Google Scholar
19. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377–82.10.1136/thorax.58.5.377Suche in Google Scholar PubMed PubMed Central
20. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219–25.10.1016/j.amjmed.2007.10.033Suche in Google Scholar PubMed
21. Jeong KY, Kim K, Kim TY, Lee CC, Jo SO, Rhee JE, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J 2011;28:122–7.10.1136/emj.2009.089383Suche in Google Scholar PubMed
22. Torres A, Ramirez P, Montull B, Menéndez R. Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012;33:266–71.10.1055/s-0032-1315638Suche in Google Scholar PubMed
23. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396–402.10.1164/ajrccm.164.3.2009052Suche in Google Scholar PubMed
24. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl 3):iii1–55.10.1136/thx.2009.121434Suche in Google Scholar PubMed
25. Arnold FW, Brock GN, Peyrani P, Rodriguez EL, Diaz AA, Rossi P, et al. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-acquired pneumonia organization (CAPO) international cohort study. Respir Med 2010;104:1736–43.10.1016/j.rmed.2010.05.022Suche in Google Scholar PubMed
26. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:10.10.1186/1471-2334-7-10Suche in Google Scholar PubMed PubMed Central
27. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006;27:9–11.10.1183/09031936.06.00130305Suche in Google Scholar PubMed
28. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: a review. QJM 2009;102: 379–88.10.1093/qjmed/hcp027Suche in Google Scholar PubMed
29. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003;21:939–43.10.1183/09031936.03.00055103Suche in Google Scholar PubMed
30. Tateda K, Kusano E, Matsumoto T, Kimura K, Uchida K, Nakata K, et al. Semi-quantitative analysis of Streptococcus pneumoniae urinary antigen: kinetics of antigen titers and severity of diseases. Scand J Infect Dis 2006;38:166–71.10.1080/00365540500400944Suche in Google Scholar PubMed
31. Hatfield KJ, Lassalle P, Leiva RA, Lindas R, Wendelboe O, Bruserud O. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology 2011;16:351–6.10.1179/102453311X13127324303434Suche in Google Scholar PubMed
32. Kruger S, Welte T. Biomarkers in community-acquired pneumonia. Expert Rev Respir Med 2012;6:203–14.10.1586/ers.12.6Suche in Google Scholar PubMed
©2014 by Walter de Gruyter Berlin Boston
Artikel in diesem Heft
- Masthead
- Masthead
- Editorial
- Point of care testing: evolving scenarios and innovative perspectives
- Review
- Point-of-care testing: where is the evidence? A systematic survey
- Mini Review
- Vulnerability of point-of-care test reagents and instruments to environmental stresses: implications for health professionals and developers
- Opinion Paper
- Twenty-five years of idiopathic calcium nephrolithiasis: has anything changed?
- Genetics and Molecular Diagnostics
- Optimizing the purification and analysis of miRNAs from urinary exosomes
- General Clinical Chemistry and Laboratory Medicine
- Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification
- Absorptive chemistry based extraction for LC-MS/MS analysis of small molecule analytes from biological fluids – an application for 25-hydroxyvitamin D
- Evaluation of 3-epi-25-hydroxyvitamin D3 cross-reactivity in the Roche Elecsys Vitamin D Total protein binding assay
- Quantification of linezolid in serum by LC-MS/MS using semi-automated sample preparation and isotope dilution internal standardization
- Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics
- Reference Values and Biological Variations
- Reference change values to assess changes in concentrations of biomarkers of exposure in individuals participating in a cigarette-switching study
- Reference values of fetal serum β2-microglobulin in the Chinese: evaluation of its clinical usefulness
- Cancer Diagnostics
- Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility
- Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results
- Radioimmunoassay of free plasma metanephrines for the diagnosis of catecholamine-producing tumors
- Infectious Diseases
- Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia
- A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness
- Letters to the Editor
- Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms
- Is magnetic resonance imaging really innocent?
- Clinical sample stability and measurement uncertainty
- A specific and sensitive activated partial thromboplastin time (APTT)-based factor VIII inhibitor screening assay
- Evaluating the inappropriateness of repeated laboratory testing in a teaching hospital of South Italy
- Could kidney glomerular filtration impairment represent the “Achilles heel” of HE4 serum marker? A possible further implication
Artikel in diesem Heft
- Masthead
- Masthead
- Editorial
- Point of care testing: evolving scenarios and innovative perspectives
- Review
- Point-of-care testing: where is the evidence? A systematic survey
- Mini Review
- Vulnerability of point-of-care test reagents and instruments to environmental stresses: implications for health professionals and developers
- Opinion Paper
- Twenty-five years of idiopathic calcium nephrolithiasis: has anything changed?
- Genetics and Molecular Diagnostics
- Optimizing the purification and analysis of miRNAs from urinary exosomes
- General Clinical Chemistry and Laboratory Medicine
- Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification
- Absorptive chemistry based extraction for LC-MS/MS analysis of small molecule analytes from biological fluids – an application for 25-hydroxyvitamin D
- Evaluation of 3-epi-25-hydroxyvitamin D3 cross-reactivity in the Roche Elecsys Vitamin D Total protein binding assay
- Quantification of linezolid in serum by LC-MS/MS using semi-automated sample preparation and isotope dilution internal standardization
- Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics
- Reference Values and Biological Variations
- Reference change values to assess changes in concentrations of biomarkers of exposure in individuals participating in a cigarette-switching study
- Reference values of fetal serum β2-microglobulin in the Chinese: evaluation of its clinical usefulness
- Cancer Diagnostics
- Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility
- Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results
- Radioimmunoassay of free plasma metanephrines for the diagnosis of catecholamine-producing tumors
- Infectious Diseases
- Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia
- A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness
- Letters to the Editor
- Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms
- Is magnetic resonance imaging really innocent?
- Clinical sample stability and measurement uncertainty
- A specific and sensitive activated partial thromboplastin time (APTT)-based factor VIII inhibitor screening assay
- Evaluating the inappropriateness of repeated laboratory testing in a teaching hospital of South Italy
- Could kidney glomerular filtration impairment represent the “Achilles heel” of HE4 serum marker? A possible further implication
